Search results for "Ejection fraction"

showing 10 items of 378 documents

Utilidad de la troponina I para predecir la disfunción sistólica en los síndromes coronarios agudos. Resultados de un estudio prospectivo y cuantitat…

2003

The relationship between troponin I and systolic function (quantitative contrast ventriculography) was evaluated in 137 consecutive patients with a first acute coronary syndrome (60 with and 77 without ST elevation). In general, a larger troponin I peak value was related with a more depressed ejection fraction and poorer regional systolic function (p < 0.0001). Nevertheless, this correlation was weaker than expected, especially in those cases without ST-segment elevation, suggesting that other factors apart from systolic dysfunction must be taken into account in order to explain the worse prognosis of those patients with increased serum levels of this marker of myocardial damage.

medicine.medical_specialtyAcute coronary syndromeEjection fractionbiologyUnstable anginabusiness.industryST elevationmedicine.diseaseTroponinInternal medicinePredictive value of testsTroponin ImedicineCardiologybiology.proteinSystoleCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

0326: Prognostic factors and impact of blood pressure level during the first 48 hours after myocardial infarction

2016

Background High blood pressure and low blood pressure are perfectly identified cardio-vascular risk factors, especially in primary prevention. However, their respective role after myocardial infarction is uncertain, with few data available. Objectives To compare cardio-vascular deaths and events after myocardial infarction between the different blood pressure levels observed during the first forty-eight hours. Methods We carried out an observational, prospective, monocentric study, including all consecutive patients admitted in Dijon’s Cardiologic Intensive Care Unit for myocardial infarction, between February 2012 and February 2014. Systolic blood pressure (SBP) was defined as the average …

medicine.medical_specialtyAcute coronary syndromeEjection fractionbusiness.industryBlood pressure level[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognostic factorsmedicine.diseaseIntensive care unitlaw.inventionSurgeryMyocardial infarctionBlood pressurelawInternal medicineCardiologyMedicineObservational studycardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessComputingMilieux_MISCELLANEOUSCardiovascular mortalityArchives of Cardiovascular Diseases Supplements
researchProduct

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

2020

Altres ajuts: This work was supported in part by Fundació La Marató de TV3 (201516-10, 201502-30), Societat Catalana de Cardiologia, "la Caixa" Banking Foundation. Altres ajuts: PERIS/SLT002-16-00234 Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' p…

medicine.medical_specialtyAngiotensin receptorEndorphins; Heart failure; Neprilysin; Sacubitril/valsartan; α-Endorphin; γ-Endorphinα‐EndorphinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]HemodynamicsPilot ProjectsHeart failure030204 cardiovascular system & hematologyγ‐EndorphinvalsartanSacubitril03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicinemedicineHumansDiseases of the circulatory (Cardiovascular) systemalpha-EndorphinOriginal Research ArticleProspective Studies030212 general & internal medicineSacubitril/valsartanγ-EndorphinAngiotensin II receptor type 1Ejection fractionbusiness.industryα-EndorphinStroke Volumegamma-Endorphinmedicine.diseaseSacubitrilValsartanRC666-701Heart failureCardiologyNeprilysinEndorphinsCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women

2021

Purpose: It is well known that anticancer drugs used for treating breast cancer can cause cardiac toxicity, and less is known about vascular toxicity. The aim of this study was to assess subclinical vascular effects of anthracyclines and trastuzumab (TRZ) in women treated for breast cancer.Methods: We enrolled 133 female patients with breast cancer undergoing adjuvant treatment with anthracycline-containing chemotherapy (CT) followed by taxane (paclitaxel/docetaxel) + TRZ. Patients underwent a standard echocardiography including measurement of left ventricular ejection fraction and global longitudinal strain at baseline and at follow-up. Vascular toxicity was evaluated by measuring brachial…

medicine.medical_specialtyAnthracyclinePhysiologypulse wave velocitycardiotoxicity030204 cardiovascular system & hematologychemotherapy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinePhysiology (medical)medicineQP1-981Pulse wave velocityvascular injuryOriginal ResearchTaxaneEjection fractionbusiness.industrymedicine.diseaseArterial stiffneBlood pressurearterial stiffness; cardiotoxicity; chemotherapy; pulse wave velocity; vascular injuryarterial stiffnessDocetaxel030220 oncology & carcinogenesisCardiologyArterial stiffnessbusinessmedicine.drugFrontiers in Physiology
researchProduct

Anomalous Origins of the Left Main Coronary Artery From the Noncoronary Sinus and of the Right Coronary Artery From the Left Sinus of Valsalva

1997

A 70-year-old man was referred for recent-onset angina. The ECG showed a right-axis deviation and signs of an old anterior infarction with loss of R waves in leads V1 through V5. Chest radiograph demonstrated a markedly enlarged heart, which was shifted to the left side with discrete signs of pulmonary congestion. Transthoracic echocardiography, which was limited by poor imaging quality, revealed a normal left ventricular cavity with reduced ejection fraction (40%) due to hypokinesia of the anterior wall. Coronary angiography showed the dominant RCA to originate from the left sinus of Valsalva. It coursed between the aorta and the pulmonary artery to the right (Figs …

medicine.medical_specialtyAortaEjection fractionmedicine.diagnostic_testbusiness.industrymedicine.diseaseAnginamedicine.anatomical_structurePhysiology (medical)Internal medicinemedicine.arteryRight coronary arteryPulmonary arterymedicineCardiologycardiovascular diseasesRadiologyEnlarged heartCardiology and Cardiovascular MedicineChest radiographbusinessArteryCirculation
researchProduct

New insights into symptomatic or silent atrial fibrillation complicating acute myocardial infarction

2015

International audience; Atrial fibrillation (AF) is the most frequent heart rhythm disorder in the general population and contributes not only to a major deterioration in quality of life but also to an increase in cardiovascular morbimortality. The onset of AF in the acute phase of myocardial infarction (MI) is a major event that can jeopardize the prognosis of patients in the short-, medium- and long-term, and is a powerful predictor of a poor prognosis after MI. The suspected mechanism underlying the excess mortality is the drop in coronary flow linked to the acceleration and arrhythmic nature of the left ventricular contractions, which reduce the left ventricular ejection fraction. The p…

medicine.medical_specialtyAsymmetric dimethylarginineSurveillance ECG en continueAsymétrique diméthylargininePopulationMyocardial InfarctionInfarctus du myocardeAcute myocardial infarctionSudden deathContinuous ECG monitoringVentricular Function Left[SHS]Humanities and Social SciencesHeart RateRisk FactorsInternal medicineCoronary CirculationHeart rateAtrial FibrillationmedicinePronosticHumansMyocardial infarctionHospital MortalityeducationHeart FailureFibrillation atriale silencieuseeducation.field_of_studyEjection fractionbusiness.industryAtrial fibrillationStroke VolumeGeneral MedicineStroke volumemedicine.diseasePrognosisMyocardial ContractionOxidative StressSilent atrial fibrillationHeart failureAsymptomatic DiseasesCardiologyEndothelium Vascular[SHS] Humanities and Social SciencesbusinessCardiology and Cardiovascular Medicine
researchProduct

Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients

2021

Abstract Aims Recent guidelines recommend a systolic blood pressure (SBP) target below 130 mmHg in heart failure patients with preserved ejection fraction (HFpEF), whatever their age. We investigated whether this intensive SBP control was associated with better survival in very old adults hospitalized for acute HFpEF. Methods and results We conducted an observational study in an acute geriatric unit: all consecutive patients discharged from hospital for acute heart failure from 1 March 2019 to 29 February 2020 with a diagnosis of HFpEF were included. Re‐hospitalization and all‐cause mortality at 1 year were compared according to the mean SBP at discharge (patients with a mean SBP < 130 mmHg…

medicine.medical_specialtyBlood PressureVentricular Function LeftElderlyInternal medicineRe‐hospitalizationDiseases of the circulatory (Cardiovascular) systemHumansMedicineMortalityMedical prescriptionProspective cohort studyAgedAged 80 and overHeart FailureEjection fractionbusiness.industryHazard ratioStroke VolumeOriginal ArticlesPreserved ejection fractionPrognosismedicine.diseaseConfidence intervalBlood pressureRC666-701Heart failureSystolic blood pressureCardiologyOriginal ArticleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (&amp;gt;40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Anthrazyklin-induzierte Kardiotoxizität: MRT des Herzens bei Kindern und Jugendlichen mit malignen Erkrankungen

2004

Purpose: Quantification of left and right ventricular function using MRI in young cancer patients treated with cardiotoxic anthracyclines. Materials and Methods: Twenty-eight patients (mean age 16.4 years) underwent cardiac MRI at 1.5 T. The study protocol consisted of morphologic T2-weighted images with fat suppression and cine steady-state free precession sequences (SSFP) for functional analysis. Seven patients were examined at the end of chemotherapy, two of them also repeatedly during therapy, and 21 patients following an average period of three years after finishing chemotherapy (range one month - 20 years) Results: The end-systolic volume index increased and the ejection fraction of t…

medicine.medical_specialtyCardiotoxicityChemotherapyEjection fractionAnthracyclinebusiness.industrymedicine.medical_treatmentCardiomyopathyCancerSteady-state free precession imagingmedicine.diseaseSurgerymedicine.anatomical_structureVentricleInternal medicinemedicineCardiologyRadiology Nuclear Medicine and imagingbusinessRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

0004 : Overweight in mice induced by perinatal programming exacerbates doxorubicin and trastuzumab cardiotoxicity

2016

Background Trastuzumab (TRZ) is believed to potentiate doxorubicin (DOX) cardiotoxicity, resulting in left ventricular dysfunction. There is some evidence that overweight could influence anticancer drug-induced cardio \toxicity, though no study has evaluated the impact of moderate overweight, induced by postnatal nutritional programming, on the cardiotoxic effects of DOX alone or in combination with TRZ. Methods Immediately after birth, litters of C57BL/6 mice were either maintained at 9 pups (normal litter, NL), or reduced to 3 (small litter, SL) in order to induce programming of ~15% overweight through postnatal overfeeding. At 4 months, NL and SL mice received a single intraperitoneal in…

medicine.medical_specialtyCardiotoxicityEjection fractionbusiness.industrymedicine.medical_treatmentIntraperitoneal injectionOverweightEndocrinologyTrastuzumabInternal medicineToxicitymedicineDoxorubicinmedicine.symptomCardiology and Cardiovascular MedicinebusinessSalinemedicine.drugArchives of Cardiovascular Diseases Supplements
researchProduct